AI-driven drug discovery platform delivers first-in-class assets and major partnership milestones

Recursion Pharmaceuticals has established itself as an AI-driven drug discovery leader with first-in-class assets REC-4881 and REC-1245, achieving significant cost savings and clinical progress. It has secured major milestone payments totaling over $525 million from strategic partnerships with Genentech and Sanofi, supported by a proprietary AI platform and data factory that enhance their innovation pipeline.

This Wire brief sits within Fusion42's coverage of Drug Discovery.